Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaler showdown: which device delivers best?

NCT ID NCT06902129

Knowledge-focused Sponsor: Petrov, Andrey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three portable inhaler devices in 10 healthy adults to see how accurately they measure airflow and record breaths. No medication was used—only a harmless salt solution. The goal was to compare device performance and user comfort, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age between 21 and 75 years * Generally healthy adult (no known systemic or chr * Normal pulmonary function (FEV1 ≥ 80% predicted at screening) * Body Mass Index (BMI) between 18.5 and 30 kg/m² * Able and willing to provide written informed consent form * Current or prior use of tabac Exclusion Criteria: * Body temperature ≥ 38.0°C on the day of screening or inhalation * Acute respiratory infection, cough, cold, or any inflammatory disease of the head and neck within the last 2 weeks * History of asthma, COPD, or other chronic pulmonary disease * History of thoracic or lung surgery * Known cardiovascular pathology, including uncontrolled or progressive hypertension * Pulmonary bleeding, hemoptysis, or blood in saliva * Diagnosed emphysema * Known bleeding disorders or use of anticoagulants * Known allergy or hypersensitivity to chitosan or related compounds * Any inhalation-induced adverse reactions during baseline assessment (e.g., cough reflex not resolving within 30 seconds) * Use of investigational drugs or participation in another clinical study within 30 days prior to enrollment * Unwillingness or inability to follow the study plan or to comply with the requirements of the informed consent agreement * Any condition which, in the opinion of the investigator, may interfere with study participation or result interpretation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Administration site injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Administration site injury Drug delivery systems Healthy volunteers Inhalation of liquid air

Contacts and locations

Locations

  • Central Contact

    Lausanne, CH-1005, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.